Pionyr Immunotherapeutics Overview

  • Founded

  • 2015

Founded
  • Status

  • Private

  • Employees

  • 70

Employees
  • Latest Deal Type

  • 2ndary - Private

  • Investors

  • 13

Pionyr Immunotherapeutics General Information

Description

Developer of cancer immunotherapies designed to target the tumor microenvironment to enhance the body's antitumor immunity. The company's immunotherapies enhance the immune system's anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity, enabling patients to combat cancer, particularly in combination with checkpoint inhibitors.

Contact Information

Website
www.pionyrtx.com
Formerly Known As
Precision Immune
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2 Tower Place
  • Suite 800
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Pionyr Immunotherapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pionyr Immunotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 01-Apr-2023 00000 Completed Clinical Trials - Phase 1
7. Secondary Transaction - Private 00000 Completed Clinical Trials - General
6. Later Stage VC 01-Jul-2020 00000 00000 00000 Completed Clinical Trials - General
5. Early Stage VC (Series B) 28-Mar-2018 0000 000.00 Completed Clinical Trials - General
4. Early Stage VC (Series A1) 04-Jan-2017 000 00.00 000.00 Completed Clinical Trials - General
3. Early Stage VC (Series A) 08-May-2015 00.000 00.000 00.000 Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Pionyr Immunotherapeutics’s complete valuation and funding history, request access »

Pionyr Immunotherapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 2,094,892 $0.000100 $0.06 $0.71 $0.71 1x $0.71 3.45%
To view Pionyr Immunotherapeutics’s complete cap table history, request access »

Pionyr Immunotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cancer immunotherapies designed to target the tumor microenvironment to enhance the body's antitumor immuni
Drug Discovery
South San Francisco, CA
70 As of 2023
00000
00000000000 00000

000000

citation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000000 00000

000000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conse
0000 000000000
Philadelphia, PA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pionyr Immunotherapeutics Competitors (70)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Marengo Therapeutics Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Philadelphia, PA 00 00000 000000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
000000 000000000 Angel-Backed New York, NY 00000 0000000000 00000
0000 000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
You’re viewing 5 of 70 competitors. Get the full list »

Pionyr Immunotherapeutics Patents

  • 25

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Pionyr Immunotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220153832-A1 Anti-marco antibodies and uses thereof Active 18-Nov-2020 000000000
US-11572407-B2 Anti-marco antibodies and uses thereof Active 18-Nov-2020 000000000 00
US-20210317211-A1 Methods of using anti-trem2 antibodies Pending 21-Aug-2019 00000000000
AU-2020218525-A1 Anti-trem1 antibodies and related methods Pending 06-Feb-2019 00000000000
CA-3128053-A1 Anti-trem1 antibodies and related methods Pending 06-Feb-2019 C07K16/2803
To view Pionyr Immunotherapeutics’s complete patent history, request access »

Pionyr Immunotherapeutics Executive Team (11)

Name Title Board Seat Contact Info
Matthew Krummel Ph.D Co-Founder & Founding Co-Chief Executive Officer
Steven James President, Co-Chief Executive Officer & Board Member
Alicia Levey Ph.D Chief Operating Officer & President
Monte Montgomery Chief Financial Officer & Executive Vice President
Evan Greger Senior Vice President & Chief Technical Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Pionyr Immunotherapeutics Board Members (12)

Name Representing Role Since
Carol Gallagher MD New Enterprise Associates Board Member 000 0000
J.C. Lopez MD Self Board Member 000 0000
Michael Ross Ph.D SV Health Investors Board Member 000 0000
Regina Salvat Ph.D Sofinnova Investments Board Member 000 0000
Rishi Gupta JD Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Pionyr Immunotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pionyr Immunotherapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gilead Sciences Corporation Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Sofinnova Investments Venture Capital Minority 000 0000 000000 0
Trinitas Capital (Beijing) PE/Buyout Minority 000 0000 000000 0
Vida Ventures (Boston) Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial